Sign In
Buy CLDX
$33.41
+0.98 (+3.02%)
At Close: Jun 22, 2026
- Late breaking Poster Presentation at AAAAI -- Ability to retreat facilitates a real-world paradigm in which treatment for ColdU and SD may be intermittent with barzolvolimab - HAMPTON, N. J. , March
- Sustained off-treatment efficacy despite barzolvolimab clearance and normalization of tryptase, suggesting disease modification in patients with CSU treated for full 52 weeks - - Greatly improved qu
Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
04:01pm, Wednesday, 25'th Feb 2026
HAMPTON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial results for the fourth quarter and year ended December 31, 2025 and provided a corporate update.
Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria
07:01am, Wednesday, 25'th Feb 2026
HAMPTON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the completion of enrollment in the Company's global Phase 3 program of barzolvolimab in chronic spontaneous urti
HAMPTON, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that multiple presentations from the Company's Phase 2 clinical trials of barzolvolimab in chronic spontaneous ur
Celldex to Present at Upcoming Investor Conferences
08:01am, Monday, 09'th Feb 2026
HAMPTON, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in fireside chats at the following upcoming investor conferences:
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Short Interest Update
04:53am, Wednesday, 21'st Jan 2026
Celldex Therapeutics, Inc. (NASDAQ: CLDX - Get Free Report) was the recipient of a significant growth in short interest in December. As of December 31st, there was short interest totaling 8,244,450 sh
MoneyShow's Best Investment Ideas For 2026: Part 3
03:20pm, Tuesday, 13'th Jan 2026
MoneyShow presents top investment ideas for 2026 from their contributors. This year's edition presents a mix of metals plays, financial stocks, deep value names, high-octane growth and tech stocks, an
Celldex Therapeutics SVPs Engage In Heavy Transactions
10:34am, Monday, 12'th Jan 2026
Multiple Senior Vice Presidents of this biotech company recently engaged in transactions that involved thousands of shares. What does this mean for the stock as it continues its long journey to regain
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Rating of “Moderate Buy” by Analysts
01:30am, Wednesday, 07'th Jan 2026
Celldex Therapeutics, Inc. (NASDAQ: CLDX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eleven research firms that are covering the stock, Marketbeat Rating
Celldex Therapeutics (NASDAQ:CLDX) Trading Up 4.1% – What’s Next?
03:38am, Friday, 02'nd Jan 2026
Celldex Therapeutics, Inc. (NASDAQ: CLDX - Get Free Report)'s share price shot up 4.1% during mid-day trading on Wednesday. The stock traded as high as $27.46 and last traded at $27.52. 215,440 shares
Celldex Therapeutics (NASDAQ:CLDX) Stock Price Crosses Above Two Hundred Day Moving Average – Here’s What Happened
03:17am, Tuesday, 30'th Dec 2025
Celldex Therapeutics, Inc. (NASDAQ: CLDX - Get Free Report) shares passed above its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $24.38 an
Corient Private Wealth LLC Purchases Shares of 201,717 Celldex Therapeutics, Inc. $CLDX
03:34am, Sunday, 21'st Dec 2025
Corient Private Wealth LLC acquired a new position in shares of Celldex Therapeutics, Inc. (NASDAQ: CLDX) in the undefined quarter, according to its most recent 13F filing with the Securities and Exch
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Average Recommendation of “Moderate Buy” from Brokerages
01:16am, Saturday, 13'th Dec 2025
Celldex Therapeutics, Inc. (NASDAQ: CLDX - Get Free Report) has received a consensus rating of "Moderate Buy" from the eleven brokerages that are presently covering the stock, MarketBeat.com reports.
Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism
08:01am, Tuesday, 09'th Dec 2025
HAMPTON, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the initiation of its global Phase 3 trial (EMBARQ-ColdU and SD) designed to establish the efficacy and safety of
